FOLFIRI is a combination chemotherapy regimen used to treat colorectal cancer. It includes a mix of drugs that work together to stop the growth of cancer cells. This regimen is often used before surgery to shrink tumors and make them easier to remove.

Targeted Therapy refers to medications that specifically target cancer cells with certain characteristics, such as specific proteins or genes. These therapies aim to attack cancer cells more precisely, potentially causing less harm to normal cells. In this trial, targeted therapy is used alongside FOLFIRI to enhance the treatment’s effectiveness against colorectal liver metastases.

Colorectal Cancer with Hepatic Metastasis – This condition occurs when cancer originating in the colon or rectum spreads to the liver. Initially, colorectal cancer may present with symptoms like changes in bowel habits, abdominal discomfort, or blood in the stool. As the disease progresses and metastasizes to the liver, patients may experience additional symptoms such as jaundice, abdominal swelling, or weight loss. The spread to the liver indicates that cancer cells have traveled through the bloodstream or lymphatic system. The progression of the disease can lead to further complications as the liver’s function becomes increasingly compromised. Monitoring and managing the disease’s progression is crucial to maintaining quality of life.